Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies

Key clinical point: Acalabrutinib showed better progression-free survival and overall survival than other frontline chronic lymphocytic leukemia therapies.

Major finding: Overall survival hazard ratios ranged from 0.18 to 0.65 in favor of acalabrutinib-based treatment, but not all were significant.

Study details: Efficacy of acalabrutinib in ELEVATE-TN was compared with data from eight other randomized, controlled trials.

Disclosures: AstraZeneca sponsored the study. The authors reported funding from AstraZeneca and numerous other pharmaceutical companies.


Davids MS et al. Clin Ther. 2020 Oct 5. doi: 10.1016/j.clinthera.2020.08.017.